17.31 USD
-0.19 (-1.09%)
17.31 USD
0 (0%)
ADMA gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. While ADMA has a great health rating, its profitability is only average at the moment. ADMA is not priced too expensively while it is growing strongly. Keep and eye on this one! With these ratings, ADMA could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
- ADMA had positive earnings in the past year.
- ADMA had a positive operating cash flow in the past year.
- ADMA had negative earnings in 4 of the past 5 years.
- In multiple years ADMA reported negative operating cash flow during the last 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 36.83%, ADMA belongs to the top of the industry, outperforming 98.68% of the companies in the same industry.
- ADMA has a better Return On Equity (48.57%) than 98.68% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 25.76%, ADMA belongs to the top of the industry, outperforming 98.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROIC | 25.76% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ADMA has a better Profit Margin (42.87%) than 97.74% of its industry peers.
- The Operating Margin of ADMA (34.19%) is better than 97.36% of its industry peers.
- ADMA's Gross Margin of 54.71% is fine compared to the rest of the industry. ADMA outperforms 76.60% of its industry peers.
- In the last couple of years the Gross Margin of ADMA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ADMA is creating value.
- The number of shares outstanding for ADMA has been increased compared to 1 year ago.
- The number of shares outstanding for ADMA has been increased compared to 5 years ago.
- The debt/assets ratio for ADMA has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 20.02 indicates that ADMA is not in any danger for bankruptcy at the moment.
- ADMA's Altman-Z score of 20.02 is amongst the best of the industry. ADMA outperforms 89.25% of its industry peers.
- ADMA has a debt to FCF ratio of 1.78. This is a very positive value and a sign of high solvency as it would only need 1.78 years to pay back of all of its debts.
- ADMA has a Debt to FCF ratio of 1.78. This is amongst the best in the industry. ADMA outperforms 93.77% of its industry peers.
- A Debt/Equity ratio of 0.16 indicates that ADMA is not too dependend on debt financing.
- ADMA's Debt to Equity ratio of 0.16 is on the low side compared to the rest of the industry. ADMA is outperformed by 64.34% of its industry peers.
- Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Altman-Z | 20.02 |
ROIC/WACC2.9
WACC8.87%
2.3 Liquidity
- ADMA has a Current Ratio of 7.13. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
- ADMA's Current ratio of 7.13 is fine compared to the rest of the industry. ADMA outperforms 70.94% of its industry peers.
- A Quick Ratio of 3.65 indicates that ADMA has no problem at all paying its short term obligations.
- With a Quick ratio value of 3.65, ADMA perfoms like the industry average, outperforming 46.60% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 |
3. Growth
3.1 Past
- ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.86%, which is quite impressive.
- ADMA shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.62%.
- ADMA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 70.84% yearly.
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
3.2 Future
- The Earnings Per Share is expected to grow by 33.00% on average over the next years. This is a very strong growth
- ADMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.50% yearly.
EPS Next Y19.34%
EPS Next 2Y33.99%
EPS Next 3Y33.26%
EPS Next 5Y33%
Revenue Next Year20.85%
Revenue Next 2Y22.49%
Revenue Next 3Y22.24%
Revenue Next 5Y21.5%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 32.06, ADMA can be considered very expensive at the moment.
- Based on the Price/Earnings ratio, ADMA is valued cheaply inside the industry as 92.64% of the companies are valued more expensively.
- ADMA is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.38, which is the current average of the S&P500 Index.
- ADMA is valuated rather expensively with a Price/Forward Earnings ratio of 19.28.
- Based on the Price/Forward Earnings ratio, ADMA is valued cheaply inside the industry as 94.15% of the companies are valued more expensively.
- The average S&P500 Price/Forward Earnings ratio is at 24.29. ADMA is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.06 | ||
| Fwd PE | 19.28 |
4.2 Price Multiples
- 93.21% of the companies in the same industry are more expensive than ADMA, based on the Enterprise Value to EBITDA ratio.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 91.51% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 101.45 | ||
| EV/EBITDA | 23.6 |
4.3 Compensation for Growth
- ADMA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- The decent profitability rating of ADMA may justify a higher PE ratio.
- ADMA's earnings are expected to grow with 33.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.66
PEG (5Y)N/A
EPS Next 2Y33.99%
EPS Next 3Y33.26%
5. Dividend
5.1 Amount
- No dividends for ADMA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
17.31
-0.19 (-1.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-12 2026-01-12/amc
Earnings (Next)05-05 2026-05-05
Inst Owners93.5%
Inst Owner Change-0.47%
Ins Owners2.35%
Ins Owner Change-0.43%
Market Cap4.12B
Revenue(TTM)488.56M
Net Income(TTM)209.45M
Analysts82.22
Price Target26.18 (51.24%)
Short Float %8.24%
Short Ratio5.96
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.96%
Min EPS beat(2)-1.96%
Max EPS beat(2)-1.96%
EPS beat(4)0
Avg EPS beat(4)-10.9%
Min EPS beat(4)-31.17%
Max EPS beat(4)-1.96%
EPS beat(8)3
Avg EPS beat(8)-42.78%
EPS beat(12)6
Avg EPS beat(12)-7.71%
EPS beat(16)8
Avg EPS beat(16)-5.59%
Revenue beat(2)1
Avg Revenue beat(2)-0.85%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)0.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)2.16%
Revenue beat(8)6
Avg Revenue beat(8)4.26%
Revenue beat(12)10
Avg Revenue beat(12)4.8%
Revenue beat(16)14
Avg Revenue beat(16)6.2%
PT rev (1m)-5.81%
PT rev (3m)-11.68%
EPS NQ rev (1m)-0.89%
EPS NQ rev (3m)4.72%
EPS NY rev (1m)-0.28%
EPS NY rev (3m)3.23%
Revenue NQ rev (1m)-0.21%
Revenue NQ rev (3m)1.63%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)0.79%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.06 | ||
| Fwd PE | 19.28 | ||
| P/S | 8.43 | ||
| P/FCF | 101.45 | ||
| P/OCF | 63.41 | ||
| P/B | 9.55 | ||
| P/tB | 9.64 | ||
| EV/EBITDA | 23.6 |
EPS(TTM)0.54
EY3.12%
EPS(NY)0.9
Fwd EY5.19%
FCF(TTM)0.17
FCFY0.99%
OCF(TTM)0.27
OCFY1.58%
SpS2.05
BVpS1.81
TBVpS1.79
PEG (NY)1.66
PEG (5Y)N/A
Graham Number4.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROCE | 32.61% | ||
| ROIC | 25.76% | ||
| ROICexc | 29.27% | ||
| ROICexgc | 29.53% | ||
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% | ||
| FCFM | 8.31% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score7
Asset Turnover0.86
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Debt/EBITDA | 0.4 | ||
| Cap/Depr | 304.79% | ||
| Cap/Sales | 4.99% | ||
| Interest Coverage | 15.23 | ||
| Cash Conversion | 37.13% | ||
| Profit Quality | 19.39% | ||
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 | ||
| Altman-Z | 20.02 |
F-Score7
WACC8.87%
ROIC/WACC2.9
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y19.34%
EPS Next 2Y33.99%
EPS Next 3Y33.26%
EPS Next 5Y33%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
Revenue Next Year20.85%
Revenue Next 2Y22.49%
Revenue Next 3Y22.24%
Revenue Next 5Y21.5%
EBIT growth 1Y45.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.1%
EBIT Next 3Y45.85%
EBIT Next 5Y36.27%
FCF growth 1Y272.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y501.56%
OCF growth 3YN/A
OCF growth 5YN/A
ADMA BIOLOGICS INC / ADMA FAQ
What is the fundamental rating for ADMA stock?
ChartMill assigns a fundamental rating of 7 / 10 to ADMA.
What is the valuation status of ADMA BIOLOGICS INC (ADMA) stock?
ChartMill assigns a valuation rating of 6 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Fairly Valued.
How profitable is ADMA BIOLOGICS INC (ADMA) stock?
ADMA BIOLOGICS INC (ADMA) has a profitability rating of 6 / 10.
What is the financial health of ADMA BIOLOGICS INC (ADMA) stock?
The financial health rating of ADMA BIOLOGICS INC (ADMA) is 8 / 10.